Expanding Vision Care Solutions with Sequel™ Lenses
Where comfort and clarity converge. Sequel democratizes premium everyday lenses through VSP®.
Newton™ is excited to announce that its innovative Sequel™ everyday lens is now included in VSP's managed vision care plan. This inclusion makes the unique Convergence Boost™ technology accessible to millions of individuals navigating a screen-centric lifestyle, which can often lead to digital eye strain.
Understanding Digital Eye Strain and Sequel™
Digital eye strain has become increasingly prevalent, affecting up to 75% of individuals who frequently use devices. With this in mind, Sequel™ stands apart by integrating Convergence Boost technology aimed at providing exceptional visual comfort and clarity tailored for the demands of modern-day usage.
Research indicates a remarkable 91% of Sequel™ wearers have experienced a significant reduction in common symptoms associated with digital eye strain, with 80% recommending it enthusiastically.
Empowering Optometrists with Innovative Solutions
Sequel™ also empowers optometric practices within the VSP network, offering them a valuable differentiator in managing visual fatigue among patients. This lens is designed for easy dispensing and aims to deliver impactful results for all who struggle with eye strain.
A Bold Step in Vision Care
As a leader in eye care innovation, Newton™ is expanding its vision care offerings with Sequel™, which addresses the widespread issues of digital eye strain. The portfolio encompasses various designs including Sequel 0, 38, 67, and PAL, ensuring that every patient struggling with visual discomfort can benefit from the advanced Convergence Boost technology.
Patient-Centric Design and Impact
Speaking about Sequel™, CEO Davis Corley shared, "Sequel is the lens patients didn't know they needed—but won't want to go without. By making it available through VSP, we are democratizing access to innovative technology that meets today's visual lifestyle demands. This partnership removes barriers and allows life-changing vision solutions to reach millions of individuals."
Insights from Eye Care Professionals
Dr. Paul Lovero, an optometrist who has fitted Sequel™, commented, "With Sequel™, my patients express that their eyes feel relaxed and free from strain. The simplicity of fitting makes it a seamless addition to my practice and is exactly what modern patients need."
This collaboration not only expands patient options but also reinforces Newton™'s commitment to improving health tech and patient outcomes. By including Sequel™ in VSP, advanced solutions to digital eye strain are made increasingly accessible.
About Newton™ and Its Innovations
Newton™ is an innovative company transforming eye care through superior patient experiences and outcomes. With its proprietary Contoured Prism technology exclusive to the Neurolens portfolio and the newly launched Sequel™ lenses, Newton™ equips eye care providers with tools to deliver significant relief to patients while raising the standard of care in the industry.
For more information about Sequel™ and ways to enhance your practice through VSP, visit www.sequellens.com.
Frequently Asked Questions
What is Sequel™ Lens Technology?
Sequel™ utilizes Convergence Boost technology to combat digital eye strain, enhancing comfort for users through innovative lens design.
How does Sequel™ differ from traditional lenses?
Unlike traditional lenses, Sequel™ is specifically designed to address digital eye strain, providing improved clarity for screen use and overall vision quality.
Can Sequel™ be used for all types of vision problems?
Yes, Sequel™ is available in various designs suitable for different visual requirements, making it adaptable for a wide range of patients.
What are the reported benefits of wearing Sequel™ lenses?
Patients have reported significant relief from symptoms of digital eye strain, with high satisfaction rates and recommendations following use of Sequel™ lenses.
How can I learn more about incorporating Sequel™ in my practice?
For more information on how to include Sequel™ in your practice, please visit www.sequellens.com for resources and details.
